CooperCompanies Q2 revenue $1.082B (+8% YoY); non-GAAP EPS $1.21 (+26%); records $271.6M litigation charge

COOPER COMPANIES, INC.

Revenue $1.082B (+8% reported, +5% organic); CooperVision $723.5M (+8%), CooperSurgical $358.0M (+8%).
GAAP diluted EPS of $(0.40) due to $271.6M net litigation charge; non-GAAP diluted EPS $1.21, up 26% YoY.
Recorded $271.6M net charge ($324.1M liabilities less $52.5M insurance) for CooperSurgical fertility media recall; settled >95% of over 1,500 claimants.
Fiscal 2026 guidance: revenue $4.285-$4.321B; non-GAAP diluted EPS $4.58-$4.66; reaffirms long-term free cash flow target >$2.2B for FY26-28.
Repurchased $13.1M in common stock (174k shares) at avg $75.84; $860.8M remaining under buyback authorization.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COOPER COMPANIES, INC. reported fiscal year 2026 results: revenue $4.285 - $4.321 billion, EPS $4.58 - $4.66.

Period: fiscal year 2026
Revenue: $4.285 - $4.321 billion
EPS: $4.58 - $4.66
Result: guidance update

Exact text from the filing

The Company updated its fiscal year 2026 financial guidance. Details are summarized as follows: • Fiscal 2026 total revenue of $4.285 - $4.321 billion (organic growth of 3.5% to 4.5%) • CVI revenue of $2.883 - $2.908 billion (organic growth of 3.5% to 4.5%) • CSI revenue of $1.402 - $1.414 billion (organic growth of 4% to 5%) • Fiscal 2026 non-GAAP diluted EPS of $4.58 - $4.66 • Reaffirm previously communicated long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COOPER COMPANIES, INC. reported fiscal second quarter ended April 30, 2026 results: revenue $1.082 billion, EPS $(0.40) per diluted share.

Period: fiscal second quarter ended April 30, 2026
Revenue: $1.082 billion
EPS: $(0.40) per diluted share
Result: reported results

Exact text from the filing

• Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter. • Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical. • Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter.

View on SEC.gov

Browse all earnings releases →

COOPER COMPANIES, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-040823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.